Identification

Name
Meprobamate
Accession Number
DB00371  (APRD01095)
Type
Small Molecule
Groups
Approved, Illicit
Description

A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.

Structure
Thumb
Synonyms
  • Meprobamat
  • Meprobamato
  • Meprobamatum
  • Meprobamic acid
External IDs
DEA No. 2820
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Meprobamate Tab 400mgTablet400 mgOralApotex Corporation1975-12-312001-10-09Canada
Equanil Tablets 400mgTablet400 mgOralWyeth Ayerst Canada Inc.1994-12-312000-03-07Canada
Meditran 400mgTablet400 mgOralMedic Laboratory LtÉe1959-12-311996-09-09Canada
Meprobamate Tab 400mgTablet400 mgOralPro Doc Limitee1959-12-312001-10-15Canada
Meprobamate Tab 400mgTablet400 mgOralDuchesnay Inc.1978-12-312001-10-15Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MeprobamateTablet200 mg/1OralAlembic Pharmaceuticals Limited2013-07-23Not applicableUs
MeprobamateTablet200 mg/1OralAlembic Pharmaceuticals Limited2015-12-01Not applicableUs
MeprobamateTablet400 mg/1OralTaro Pharmaceutical Industries, Ltd.2011-05-23Not applicableUs
MeprobamateTablet200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2011-05-23Not applicableUs
MeprobamateTablet400 mg/1OralActavis Pharma Company1973-05-03Not applicableUs
MeprobamateTablet200 mg/1OralAvera Mc Kennan Hospital2015-11-032018-06-13Us
MeprobamateTablet400 mg/1OralDr Reddy's Laboratories2008-01-03Not applicableUs
MeprobamateTablet200 mg/1OralTaro Pharmaceutical Industries, Ltd.2011-05-23Not applicableUs
MeprobamateTablet400 mg/1OralHeritage2009-05-012018-01-13Us
MeprobamateTablet400 mg/1OralAlembic Pharmaceuticals Limited2015-12-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
282 Mep TabMeprobamate (200 mg) + Acetylsalicylic acid (350 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-311998-08-14Canada
Equagesic TabletsMeprobamate (200 mg) + Acetylsalicylic acid (250 mg) + Ethoheptazine citrate (75 mg)TabletOralWyeth Ayerst Canada Inc.1995-12-311997-01-14Canada
International/Other Brands
Equanil (Wyeth) / Meprospan / Miltown (Wallace Laboratories)
Categories
UNII
9I7LNY769Q
CAS number
57-53-4
Weight
Average: 218.2502
Monoisotopic: 218.126657074
Chemical Formula
C9H18N2O4
InChI Key
NPPQSCRMBWNHMW-UHFFFAOYSA-N
InChI
InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate
SMILES
CCCC(C)(COC(N)=O)COC(N)=O

Pharmacology

Indication

For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.

Associated Conditions
Pharmacodynamics

Meprobamate is an anxiolytic drug. It was the best selling minor tranquilizer for a time but has largely been replaced by benzodiazepines. Meprobamate has most of the pharmacological effects and dangers of the barbiturates (though it was marketed as being safer). However, it is less sedating at effective doses. It is reported to have some anticonvulsant properties against absence seizures, but can exacerbate generalized tonic-clonic seizures. It has also been used as a hypnotic (sleeping pill). However, its is currently only licensed as an anxiolytic and it is a third or fourth-order choice.

Mechanism of action

Meprobamate's mechanism of action is not known. It has been shown in animal studies to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Meprobamate binds to GABAA receptors which interrupt neuronal communication in the reticular formation and spinal cord, causing sedation and altered perception of pain.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
AGamma-aminobutyric acid receptor subunit alpha-2
agonist
Human
AGamma-aminobutyric acid receptor subunit alpha-3
agonist
Human
AGamma-aminobutyric acid receptor subunit alpha-4
agonist
Human
AGamma-aminobutyric acid receptor subunit alpha-5
agonist
Human
AGamma-aminobutyric acid receptor subunit alpha-6
agonist
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

Plasma half-life is about 10 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. Death has been reported with ingestion of as little as 12 g meprobamate and survival with as much as 40 g.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Capecitabine Metabolism PathwayDrug metabolism
Capecitabine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Meprobamate can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Meprobamate.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amperozide.Experimental
ApalutamideThe serum concentration of Meprobamate can be decreased when it is combined with Apalutamide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Meprobamate can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Azaperone.Investigational, Vet Approved
AzelastineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzyl alcohol.Approved
BortezomibThe metabolism of Meprobamate can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Meprobamate.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bupivacaine.Approved, Investigational
BuprenorphineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Meprobamate is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Meprobamate can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Meprobamate can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlordiazepoxide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Meprobamate can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Meprobamate can be decreased when combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Meprobamate can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Meprobamate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Meprobamate.Approved
CocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Meprobamate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Meprobamate can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate.Approved
DabrafenibThe serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine.Investigational
DelavirdineThe metabolism of Meprobamate can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Meprobamate is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Meprobamate.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Meprobamate.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Meprobamate is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Meprobamate.Approved
EfavirenzThe metabolism of Meprobamate can be decreased when combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Meprobamate can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Meprobamate can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone.Approved, Investigational
EthanolMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Meprobamate can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Meprobamate.Approved
EzogabineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Meprobamate can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Meprobamate can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Meprobamate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Meprobamate can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Meprobamate can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital.Approved
HydrocodoneMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Meprobamate can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indiplon.Investigational
IsocarboxazidThe therapeutic efficacy of Meprobamate can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Meprobamate can be decreased when combined with Isoniazid.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Meprobamate can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Meprobamate.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.Approved
LobeglitazoneThe metabolism of Meprobamate can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Meprobamate can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Meprobamate can be increased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Meprobamate can be increased when it is combined with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Meprobamate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Meprobamate can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Meprobamate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Meprobamate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital.Approved
MethotrimeprazineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital.Approved
MetyrosineMeprobamate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Investigational
MirtazapineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Meprobamate can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Meprobamate can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Meprobamate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Meprobamate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Meprobamate can be decreased when combined with Nelfinavir.Approved
NicardipineThe metabolism of Meprobamate can be decreased when combined with Nicardipine.Approved, Investigational
NicotineThe metabolism of Meprobamate can be decreased when combined with Nicotine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Meprobamate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Meprobamate can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Meprobamate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.Approved
PantoprazoleThe metabolism of Meprobamate can be decreased when combined with Pantoprazole.Approved
ParaldehydeMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Meprobamate.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
PerazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Meprobamate can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pomalidomide.Approved
PramipexoleMeprobamate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Meprobamate.Approved
PSD502The risk or severity of adverse effects can be increased when Meprobamate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Meprobamate.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Meprobamate.Approved, Investigational
RifampicinThe metabolism of Meprobamate can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Meprobamate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Romifidine.Vet Approved
RopiniroleMeprobamate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ropivacaine.Approved
RotigotineMeprobamate may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Meprobamate can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Meprobamate.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Meprobamate can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Meprobamate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
StiripentolThe metabolism of Meprobamate can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sultopride.Experimental
SuvorexantMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrodotoxin.Investigational
ThalidomideMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Meprobamate can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe metabolism of Meprobamate can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Meprobamate.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Meprobamate is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vigabatrin.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Meprobamate.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Meprobamate can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zolazepam.Vet Approved
ZolpidemMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Meprobamate can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014515
KEGG Drug
D00376
PubChem Compound
4064
PubChem Substance
46508142
ChemSpider
3924
ChEBI
6761
ChEMBL
CHEMBL979
Therapeutic Targets Database
DAP001507
PharmGKB
PA450377
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Meprobamate
ATC Codes
N05CX01 — Meprobamate, combinationsN05BC51 — Meprobamate, combinationsN05BC01 — Meprobamate
MSDS
Download (52.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline llc
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Wyeth ayerst laboratories
  • Ferndale laboratories inc
  • Alra laboratories inc
  • Teva pharmaceuticals usa inc
  • Alembic ltd
  • Barr laboratories inc
  • Elkins sinn div ah robins co inc
  • Heather drug co inc
  • Impax laboratories inc
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Ivc industries inc dba inverness medical nutritionals group
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Km lee laboratories inc
  • Mallard inc
  • Mk laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nexgen pharma inc
  • Parke davis div warner lambert co
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Scherer laboratories inc
  • Solvay pharmaceuticals
  • Stanlabs pharmaceutical co sub simpak corp
  • Tablicaps inc
  • Usl pharma inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Halsey drug co inc
Packagers
  • C.O. Truxton Inc.
  • Calvin Scott and Co. Inc.
  • Dispensing Solutions
  • Doctor Reddys Laboratories Ltd.
  • GlaxoSmithKline Inc.
  • Group Health Cooperative
  • Heritage Pharmaceuticals
  • InvaGen Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mikart Inc.
  • Nexgen Pharma Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Qualitest
  • United Research Laboratories Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral
TabletOral400 mg
TabletOral200 mg/1
TabletOral400 mg/1
TabletOral200 mg
Prices
Unit descriptionCostUnit
Mepron 750 mg/5ml Suspension5.41USD ml
Mepron 750 mg/5 ml suspension4.95USD ml
Meprobamate 200 mg tablet1.42USD tablet
Meprobamate 400 mg tablet0.84USD tablet
Meprozine 50-25 mg capsule0.78USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6649659Yes1997-01-102017-01-10Us
US4981874No1992-08-152009-08-15Us
CA2152615No2001-10-162013-12-23Canada
CA1336266No1995-07-112012-07-11Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105 °CPhysProp
water solubility4700 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.70HANSCH,C ET AL. (1995)
logS-1.67ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility2.47 mg/mLALOGPS
logP1.06ALOGPS
logP0.93ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)15.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.64 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity53.04 m3·mol-1ChemAxon
Polarizability22.65 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9534
Blood Brain Barrier+0.9864
Caco-2 permeable-0.5731
P-glycoprotein substrateNon-substrate0.5282
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9033
Renal organic cation transporterNon-inhibitor0.945
CYP450 2C9 substrateNon-substrate0.9108
CYP450 2D6 substrateNon-substrate0.8961
CYP450 3A4 substrateNon-substrate0.7032
CYP450 1A2 substrateNon-inhibitor0.8381
CYP450 2C9 inhibitorNon-inhibitor0.8799
CYP450 2D6 inhibitorNon-inhibitor0.8764
CYP450 2C19 inhibitorNon-inhibitor0.8754
CYP450 3A4 inhibitorNon-inhibitor0.8735
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8914
Ames testNon AMES toxic0.8706
CarcinogenicityNon-carcinogens0.7304
BiodegradationNot ready biodegradable0.965
Rat acute toxicity2.4075 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9943
hERG inhibition (predictor II)Non-inhibitor0.9322
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-053u-9100000000-d890d15ca6738ce72f60
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-1900000000-8dd8e00d9af9bce5cd26
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052b-9100000000-c21398e92cac7b48f567
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9000000000-dd49a24a00b896129dbb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9000000000-c537c5c82280244f0974
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9000000000-f351c8e0d2b10b45fdc9

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Carbamate esters
Alternative Parents
Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on June 16, 2018 22:04